课题基金 / 基金详情

Control of type III interferon expression and Herpes simplex virus type 1 replication by miR-200

Control of type III interferon expression and Herpes simplex virus type 1 replication by miR-200
miR-200 对 III 型干扰素表达和 1 型单纯疱疹病毒复制的控制
批准号:
MR/P011349/1
负责人:
Jurgen Haas
金额:
$69.05万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --

项目摘要

项目成果

Jurgen Haas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Interferons are proteins that are released by cells to combat viruses. There are 3 different types of interferons which differ by the cells that produce them but also the pathogens against which they are active. In our previous work using a new type of genomic screen we showed that the virus that causes cold sores and some other diseases, Herpes simplex virus type 1 (HSV-1), is mainly controlled by a so-called type III interferon (IFN-lambda). Micro RNAs (miRNAs) are small pieces of genetic material within cells that control which proteins are produced. In our recent work we applied another type of genomic screen and identified which miRNAs combat HSV-1. In this project we will combine the outcome of these two genomic screens to investigate how antiviral miRNAs work. From other work which we recently did we know that one of them, miR-200, leads to an increase of IFN-lambda. miR-200 is known to be regulated by an inhibitory protein called ZEB1, but also inhibits ZEB1 itself. This regulatory feedback loop between miR-200 and ZEB1 is known to control a range of different biological processes, both in normal development and cancer. In this project we will investigate if miR-200 inhibits HSV-1 through ZEB1 and IFN-lambda. If this is the case, miRNA creates a functional link between the immune response, normal development and cancer. Our unique approach will help to understand the mechanisms of antiviral miRNAs and could be instrumental for the development of novel drugs against viruses and cancer.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.jhin.2023.02.010
发表时间: 2023-05
期刊: JOURNAL OF HOSPITAL INFECTION
影响因子: 6.9
作者: [Cotton, S., McHugh, M. P., Dewar, R., Haas, J. G., Templeton, K.]
通讯作者: Templeton, K.
DOI: 10.18632/oncotarget.24946
发表时间: 2018-04-06
期刊: Oncotarget
影响因子: --
作者: [Bhatia R, Kavanagh K, Stewart J, Moncur S, Serrano I, Cong D, Cubie HA, Haas JG, Busby-Earle C, Williams ARW, Howie SEM, Cuschieri K]
通讯作者: Cuschieri K
DOI: 10.1186/s12866-022-02671-2
发表时间: 2022-12-22
期刊: BMC MICROBIOLOGY
影响因子: 4.2
作者: [Hu, Xinyue, Haas, Juergen G., Lathe, Richard]
通讯作者: Lathe, Richard
DOI: 10.1109/jerm.2021.3077110
发表时间: 2022-03
期刊: IEEE journal of electromagnetics, RF and microwaves in medicine and biology
影响因子: --
作者: [Kossenas K, Podilchak SK, Comite D, Re PDH, Goussetis G, Pavuluri SK, Griffiths SJ, Chadwick RJ, Guo C, Bruns N, Tait-Burkard C, Haas JG, Desmulliez MPY]
通讯作者: Desmulliez MPY
Phenotypical and functional modulation of B-lymphocytes by KSHV infection
  • 批准号:
    G0501453/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $78.99万
  • 财政年份:
    2007
  • 负责人:
    Jurgen Haas
  • 依托单位:
国内基金
海外基金
铋基邻近双金属位点Type B异质结光热催化合成氨机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2024
  • 负责人:
    黎景卫
  • 依托单位:
盐皮质激素受体抑制2型固有淋巴细胞活化加重心肌梗死后心室重构的作用机制
  • 批准号:
    82372202
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    侯旭敏
  • 依托单位:
损伤线粒体传递机制介导成纤维细胞/II型肺泡上皮细胞对话在支气管肺发育不良肺泡发育阻滞中的作用
  • 批准号:
    82371721
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    王星云
  • 依托单位:
GPSM1介导Ca2+循环-II型肌球蛋白网络调控脂肪产热及代谢稳态的机制研究
  • 批准号:
    82370879
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    严婧
  • 依托单位: